Senseonics Holdings Remains On-target To Achieve Annual Growth Of ~50% In Patient Installed Base At The End Of 2024 As Compared With 2023; Reiterates FY24 Global Net Revenue Guidance Of ~$22M
Senseonics Holdings Remains On-target To Achieve Annual Growth Of ~50% In Patient Installed Base At The End Of 2024 As Compared With 2023; Reiterates FY24 Global Net Revenue Guidance Of ~$22M
senseonics公司預計到2024年患者安裝基礎年增長約50%，相比於2023年；重申2024財年全球營業收入指導約爲2200萬美元
Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today provided commercial updates related to the Eversense 365 launch.
Senseonics控股公司（紐交所：SENS），是一家專注於開發和製造長期植入式連續血糖監測（CGM）系統的醫療科技公司，主要針對糖尿病患者，今天提供了與Eversense 365發佈相關的商業更新。
Eversense 365 Commercial Launch Update
Eversense 365商業發佈更新
- Launched Eversense 365 in October with global commercial partner Ascensia Diabetes Care and began shipping product in November
- Seeing strong interest in Eversense 365, as evidenced by the following early launch performance indicators:
- Direct-to-Consumer (DTC) leads in each of October and November were more than double the number of leads in pre-launch months
- New patient shipments in November were the highest compared to any month since inception of the Ascensia partnership
- Since launch, Eversense 365 has already shown a 42% increase in the number of providers prescribing Eversense and a 69% increase in prescriptions from top prescribers compared to the pre-launch rate in 2024
- One-third of Eversense 365 prescribers are new first-time Eversense prescribers
- The number of patients switching to Eversense monthly from competitive CGMs has increased 47% since Eversense 365 launch
- Remain on-target to achieve annual growth of approximately 50% in patient installed base at the end of 2024 as compared with 2023
- Reiterated full-year 2024 global net revenue guidance of approximately $22 million
- Reiterated full-year 2024 global net revenue guidance of approximately $22 million
- 與全球商業合作伙伴Ascensia Diabetes Care於10月推出Eversense 365，並於11月開始發貨
- 看到對Eversense 365的強烈興趣，以下是早期發佈的表現因子：
- 在10月和11月期間，直接面向消費者(DTC)的潛在客戶數量是發佈前幾個月的兩倍以上
- 11月份的新患者發貨量是自Ascensia合作以來的最高記錄
- 自推出以來，Eversense 365已經顯示出處方Eversense的提供者數量增加了42%，而來自主要處方者的處方數量較2024年推出前的比例增加了69%。
- 三分之一的Eversense 365處方者是首次開處方Eversense的新手。
- 自Eversense 365推出以來，每月轉向Eversense的患者人數比競爭性連續血糖監測儀增加了47%。
- 預計到2024年年底，實現患者安裝基礎年增長約50%的目標，較2023年相比。
- 重申2024財年的全球淨營業收入指引約爲2200萬。
- 重申2024財年的全球淨營業收入指引約爲2200萬。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間